Antengene's (HKG:6996) Chief Financial Officer Donald Andrew Lung resigned effective Aug. 1 to pursue other career opportunities, according to a Friday Hong Kong bourse filing.
Separately, the cancer therapy developer named Rui Guo as its chief business officer with effect from the same day. Guo has been a part of the Company since 2017.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.